ADXN (ADXN) Stock Price & Analysis
ADXN (ADXN) rose 0.00% to USD 5.89 as of July 25, 2026 at 22:25 UTC, according to Nexqual real-time market data.
ADXN last closed at USD 5.89; the session ranged USD 5.89–5.89 on volume of 195 shares. Market capitalization is $7.45M, with a 52-week range of USD 5.41–12.05 (NCM). Source: Nexqual, July 25, 2026 at 22:25 UTC.
Key Statistics (as of July 25, 2026 at 22:25 UTC)
| Price | USD 5.89 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 5.89 |
| Open | USD 5.89 |
| Day Range | USD 5.89 – 5.89 |
| 52-Week Range | USD 5.41 – 12.05 |
| Volume | 195 shares |
| Market Cap | $7.45M |
| Exchange | NCM |
Technical Analysis (ADXN)
Nexqual's technical model rates ADXN "SELL" based on 1 bullish and 4 bearish signals across 125 daily candles, as of July 25, 2026 at 22:25 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 50.4 (neutral) |
| vs SMA50 | Below (USD 6.24) |
| MACD | -0.1 (negative) |
Analyst Ratings (ADXN)
Wall Street analysts rate ADXN "None", per Nexqual as of July 25, 2026 at 22:25 UTC.
| Consensus Rating | None |
|---|
Earnings (ADXN)
Source: Nexqual, July 25, 2026 at 22:25 UTC.
Financials & Fundamentals (ADXN)
| Total Revenue | $109,496 |
|---|---|
| Revenue Growth (YoY) | -89.20% |
| Gross Margin | +0.00% |
| Operating Margin | -6238.81% |
| Profit Margin | +0.00% |
| ROE | -122.28% |
| Debt / Equity | 3.11 |
| Current Ratio | 0.97 |
| Total Cash | $935,153 |
| Total Debt | $102,269 |
| Free Cash Flow | $-1.52M |
Source: Nexqual, July 25, 2026 at 22:25 UTC.
Financial Health Score (ADXN)
Nexqual rates ADXN's overall financial health "Weak" across five dimensions, as of July 25, 2026 at 22:25 UTC.
| Growth | Critical — Revenue -75% YoY (annual), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Solid — $935K cash, no debt |
| Cash Flow | Weak — FCF negative: -$2M, burning cash |
| Efficiency | Critical — ROE -122%, ROA -23.6% |
Ownership (ADXN)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.04% |
| Shares Outstanding | 1.27M |
| Float | 808,873 |
| Short % of Float | +0.09% |
Source: Nexqual, July 25, 2026 at 22:25 UTC.
Leadership (ADXN)
ADXN is led by Timothy Mark Dyer (age 57), Co-Founder, CEO & Director, per Nexqual as of July 25, 2026 at 22:25 UTC.
| Co-Founder, CEO & Director | Timothy Mark Dyer (age 57) |
|---|---|
| Chief Medical Officer & Director | Roger G. Mills (age 68) |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AFIB | Acutus Medical Inc. | USD 0 | ▲ 0% |
| NMAD | Nomad Power Solutions, Inc. | USD 4.84 | ▼ 3.01% |
| DRMA | Dermata Therapeutics, Inc. | USD 1.32 | ▲ 4.76% |
| KZIA | Kazia Therapeutics Limited | USD 12.26 | ▼ 16.03% |
| BCDA | BioCardia, Inc. | USD 0.85 | ▼ 6.59% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: July 25, 2026 at 22:25 UTC. This page is informational and not investment advice.